H7N9 is a designated subtype of species influenza virus A which is on certain occasions found in birds, however does not necessarily infect humans. H7N9 is also termed as bird flu virus or avian influenza virus. Avian influenza A H7 viruses usually mobilize and disseminate between avian populations along with a few versions that are known to sometimes infect humans. Similar to all influenza A viruses, there are several strains of H7N9. According to a study done on H7N9 vaccine market, starting at the end of March 2013, China accounted human and poultry infections with a novel strain on H7N9 and which turned out to be quite different from H7N9 viruses seen earlier.The first case of H7N9 virus that infected humans was reported in March 2013, in China. Thereon the number of cases maintained to exist throughout the month of April and later dropped to just a handful cases in the summer months. Towards the end of 2013, a total of 144 cases had been actively reported, out of which 46 had died.Research proved that the influenza virus had a tendency to attack in winters. In 2014 January, 96 affirmed reports of the disease were reported and 19 deaths. The World Health Organization (WHO) has determined H7N9 as “an unusually dangerous virus for humans.” Majority of the cases lead to extreme respiratory illness, along with death rate of approximately 30 percent.Amongst the patients who were infected with this influenza virus, researchers say that there was a strange popularity of older males. Even though many environmental, biological, and behavioural explanations for this pattern have been suggested, the actual reason still remains unknown.
Evidences say that many people have been infected with the virus post having contact with either contaminated surroundings of infected poultry. The symptoms on infected people start with cough and fever. Many patients have further advanced to severe illness, which includes chronic pneumonia, septic shock, acute respiratory distress syndrome (ARDS), and eventually multiple organ failure resulting in death.Chinese scientists declared that they has successfully developed an H7N9 vaccine on October 26, 2013, it was the first influenza vaccine to be made completely in China. The H7N9 vaccine was collectively developed by research scientists from Chinese Centre for Disease Control and Prevention, Zhejiang University, Hong Kong University, the Chinese Academy of Medical Sciences and China's National Institute for Food and Drug Control.This vaccine was made from a throat swab of an infected patient.On November 12, 2013, scientists from the United States at Novavax, Inc. stated their productive clinical testing of an H7N9 vaccine in New England Journal of Medicine. The inactivated vaccine was made with H7N9 virus which was insulated in Shanghai, China. Additives have been tested with the vaccine to conclude whether a satisfactory response is produced. Furthermore, at the time of pandemic, additives might be used as a part of a ‘dose-sparing strategy’.